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Response to: Mortality Rate of Bullous Pemphigoid
in a US Medical Center
To the Editor:
Colbert et al (2004) recently reported a 1 y overall survival
probability of 89% with a 95% confidence interval (CI) of
76%–94% from a retrospective series of 38 bullous pem-
phygoid (BP) patients managed in a single institution in the
United States (US). They hypothesized that the seemingly
better prognosis of BP patients in their series as compared
with four European ones (Bernard et al, 1997; Roujeau et al,
1998; Joly et al, 2002; Rzany et al, 2002) may be because of
differences in practice patterns, because hospitalization is
the standard procedure in Europe and may favor sepsis,
whereas most patients in their series were outpatients. We
question their hypothesis on the following grounds.
First, we note that the 1 y survival probability in Colbert
et al was obtained from only four deaths. It seems prob-
lematic to compare figures from such a small single center
retrospective study in which patients received widely var-
iable treatment regimens (as underlined in the Editorial by
Swerlick and Korman, 2004), with those from four large Eu-
ropean studies that included more than 600 patients overall,
two of them being prospective studies with treatment de-
fined in an homogeneous and standardized manner.
Second, it seems surprising that only 38 BP patients
were managed at the Medical College of Wisconsin Affili-
ated Hospitals within a period of 5 y and 4 mo. Indeed,
the web site of the Medical College of Wisconsin (http://
www.mcv.edu/) evaluates the population of the greater Mi-
lwaukee area at 1.4 million. Based on the estimated inci-
dence of BP of 10 cases per million population in the US
reported by Colbert et al, 75 incident BP cases would have
been expected from the referral area during the time of their
study. Thus, the recruitment in their series corresponded to
about half of what was expected. One possible explanation
for this discrepancy is that the more disabled and older
patients, who are at higher risk of dying in our experience,
were managed outside the Medical College of Wisconsin
Affiliated Hospital. Whatever the precise explanation for this
discrepancy, it points to a possible selection of the healthier
patients in the series of Colbert et al. Thus, it would seem
crucial to understand who were the missing patients, where
and how they were treated, and what their outcome was.
Third, the mean age of patients from the series of Colbert
et al was 77 y, as compared with 81 y in our recent clinical
trial (Joly et al, 2002). Because the probability of death of
the French population with the same age and sex distri-
bution as our patients has been estimated in the range
7%–10% per year (Roujeau et al, 1998), this age difference
may account for the differences observed in survival be-
tween the series of Colbert et al and ours.
Fourth, because of the retrospective design of their study,
Colbert et al were not able to assess patients’ general con-
dition accurately. In our recent prospective study including
more than 300 patients treated homogeneously with a stand-
ardized treatment regimen, we found that the Karnofsky
score (which is a measure of a patient’s general condition on
a scale ranging from 0 to 100) was the main prognostic factor
of BP, in addition to age (Joly et al, 2005). A significant pro-
portion of BP patients included in the four recent European
studies were in poor general condition. For instance, the
mean Karnofsky score of BP patients included in our recent
clinical trial was 64; one-third of our patients were bedridden
and had a Karnofsky score of 40 or less (Joly et al, 2002). It
would be key to account for initial Karnofsky scores of pa-
tients in the study by Colbert et al upon comparing their
survival with that from patients in European studies.
Finally, to test the hypothesis of Colbert et al that appar-
ent differences in survival may be because of lower hospi-
talization rates in their series, we compared the overall
survival of the 39 BP patients initially managed as outpa-
tients with that of the 302 patients who were initially hos-
pitalized in our recent clinical trial (Joly et al, 2002). We
observed very similar 1 y overall survival rates of 72% (95%
CI 58%–86%) and 67% (95% CI 62%–73%), respectively.
This lack of significant difference in survival between the
two groups (p¼ 0.65, log-rank test) suggests that differ-
ences in the initial management of BP patients were not
responsible for any major differences in survival.
In conclusion, we think that the older age of European BP
patients and their poorer general condition are more likely
responsible for differences in survival between the US and
Europe, rather than differences in practice patterns. Differ-
ences in hospital care systems may explain differences in
referral patterns between the US and Europe. Large pro-
spective multicenter studies from the US would be useful to
improve our prognostic knowledge of BP and allow mean-
ingful comparisons between the US and Europe.
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